Kiniksa Pharmaceuticals Ltd

KNSA · Moat type: REGULIERUNG

MoatScore

7/10

Fair Value

41 USD

Margin of Safety

-55.7 %

Rating

BEOBACHTEN

GESCHÄFTSMODELL Kiniksa Pharmaceuticals is a biopharmaceutical company specializing in rare inflammatory and cardiovascular diseases that generates revenues primarily from the sale of approved medications and defends its value through regulatory product exclusivity protections.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.